Xlife Sciences AG / Key word(s): IPO Zurich, 23rd of December 2024: Xlife Sciences AG (SIX: XLS) is pleased to announce that its portfolio company, FUSE-AI GmbH, is engaged in discussions regarding a potential acquisition by Pineapple Power Corporation PLC, a UK-based company listed on the London Stock Exchange. The proposed transaction would represent a significant milestone in FUSE-AI GmbH’s journey to expand its innovative AI-powered solutions for the clinical sector. The acquisition would include all shares of FUSE-AI GmbH, with the consideration to be provided in the form of shares issued by Pineapple Power Corporation PLC. This transaction, if finalized, would constitute a reverse takeover under the UK Listing Rules, paving the way for FUSE-AI GmbH to access global capital markets and further expand its operations. The proposed transaction is expected to value FUSE-AI GmbH at EUR 80-90 million, reflecting its strong market potential and technological leadership in the field of medical AI. Pineapple Power Corporation PLC intends to acquire 100% of the issued share capital of FUSE-AI GmbH, with Xlife Sciences AG, as the largest shareholder with a 42.25% stake, set to significantly benefit from this milestone transaction. This valuation and stake highlight the strategic importance of FUSE-AI GmbH within Xlife Sciences AG’s portfolio and the broader healthcare innovation landscape. Matthias Steffens, CEO of FUSE-AI GmbH, stated: «This development highlights the strong position of FUSE-AI GmbH in delivering cutting-edge AI solutions for clinical diagnostics. We are excited about the opportunities this collaboration can bring in reaching new markets and driving innovation.» Oliver R. Baumann, CEO of Xlife Sciences AG, commented: «The potential acquisition of FUSE-AI GmbH by Pineapple Power Corporation PLC underscores the strength of Xlife Sciences AG’s approach to fostering groundbreaking technologies and providing them with strategic paths to growth and scalability. This transaction exemplifies our commitment to bridging the gap between research and commercialization.» FUSE-AI GmbH is recognized for its innovative solution, «Prostate.Carcinoma.ai», which significantly enhances the efficiency and accuracy of prostate MRI analysis. With additional applications under development and an established distribution network in over 42 countries, FUSE-AI GmbH is well-positioned for continued growth in the field of medical AI. Further details about the proposed acquisition and transaction timeline will be shared as they become available.
Financial calendar
Kontakt Xlife Sciences AG, End of Inside Information |
Language: | English |
Company: | Xlife Sciences AG |
Talacker 35 | |
8001 Zürich | |
Switzerland | |
Phone: | +41 44 385 84 60 |
E-mail: | info@xlifesciences.ch |
Internet: | www.xlifesciences.ch |
ISIN: | CH0461929603 |
Valor: | A2PK6Z |
Listed: | SIX Swiss Exchange |
EQS News ID: | 2057105 |
End of Announcement | EQS News Service |
|
2057105 23-Dec-2024 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.